OvaScience Inc (NASDAQ:OVAS) shares shot up 7.5% during mid-day trading on Monday . The company traded as high as $0.82 and last traded at $0.74. 4,600 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 285,257 shares. The stock had previously closed at $0.80.

Separately, ValuEngine raised shares of OvaScience from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.

The firm has a market cap of $29.36 million, a PE ratio of -0.60 and a beta of 3.34.

Several institutional investors and hedge funds have recently modified their holdings of OVAS. Sabby Management LLC increased its stake in shares of OvaScience by 143.6% during the 1st quarter. Sabby Management LLC now owns 1,461,525 shares of the biotechnology company’s stock worth $1,185,000 after purchasing an additional 861,525 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of OvaScience by 6,531.3% during the 4th quarter. Renaissance Technologies LLC now owns 782,165 shares of the biotechnology company’s stock worth $1,095,000 after purchasing an additional 770,370 shares in the last quarter. Deutsche Bank AG increased its stake in shares of OvaScience by 7,476.4% during the 4th quarter. Deutsche Bank AG now owns 517,693 shares of the biotechnology company’s stock worth $724,000 after purchasing an additional 510,860 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of OvaScience by 217.6% during the 1st quarter. Wells Fargo & Company MN now owns 473,876 shares of the biotechnology company’s stock worth $384,000 after purchasing an additional 324,685 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new position in shares of OvaScience during the 4th quarter worth approximately $342,000. 24.87% of the stock is owned by institutional investors and hedge funds.

OvaScience Company Profile (NASDAQ:OVAS)

OvaScience, Inc, a fertility company, discovers, develops, and commercializes fertility treatment options for women and families struggling with infertility worldwide. Its patented technology is based on the discovery about the existence of egg precursor (EggPC) cells to transform the treatment landscape for women's fertility.

Featured Story: Market Capitalization – What it Means for Investors

Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.